By Kamal Choudhury Oct 22 (Reuters) – Moderna's shares sank over 25% on Thursday as late-stage trial data for its personalized melanoma vaccine, developed with Merck, triggered what analysts called a
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
THE DAYBOOK FOR VICE PRESIDENT VANCE Friday, October 23, 2026 ----- The daybook editor is…
VIDEO SHOWS: ARGENTINIAN SOCCER STAR LIONEL MESSI ADDRESSING SCHOOL COMMUNITY / SOUNDBITES FROM MESSI /…
By Michael Erman and Julie Steenhuysen Oct 22 (Reuters) - Moderna and Merck said on…
* Protests take place in Caracas, Valencia, Maracay, San Cristobal and Maracaibo * Ruling party…
Oct 22 (Reuters) - Major US banks have been blocking third-party AI agents from operating…
MILWAUKEE -- After almost a decade as a franchise cornerstone, Milwaukee Brewers right-hander Brandon Woodruff…